Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: dwc who wrote (26820)	12/8/1998 3:41:00 PM
From: bob zagorin	Read Replies (1) \| Respond to of 32384

Do your research and buy a basket of advanced biotech stocks to spread the risk and participate in the maturation and consolidation of this industry.

To: dwc who wrote (26820)	12/8/1998 5:42:00 PM
From: Henry Niman	Respond to of 32384

CNBC just did a review. Noted that it was the 3rd European merger in a few months (HOE/RP and Sanofi/Synthelabo happened last month). Hemant Shah indicated that both companies were research driven and highly focused. Astra was losing patent protection and the new company would have $13 Billion in sales in 1999 treating cancer, ulcers, and respiratory problems. Shah indicated more mergers were inevitable because that was the only way that $100-$200 Billion companies could generate 20-30% growth rates. Large US companies not likely to merge were said to be PFE, WRK, and WLA.

To: dwc who wrote (26820)	12/9/1998 5:39:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

CNBC just reported that the new company will be called Astra/Zeneca. It will be an all stock deal and 6000 jobs will be cut worldwide. The merger will cost about $1.2 Billion. In Europe ZEN is up 4.5%, AAB up 12%, PNU up 2%, RP up 1.3%, Schering up 1%, Bayer down 0.5%.

To: dwc who wrote (26820)	12/9/1998 7:44:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

CNBC just did another update on AstraZeneca. They noted that overall companies were not leaders, but Astra was leading in treating ulcers and Zeneca was leading in cancer. Merger driven by patent expirations in 2001 as well as research costs. Noted that RP/HOE and Novartis were large competitors and speculated that AstraZeneca could be merged with another pharma.